Due to COVID-19, HCA’s lobby is closed. Learn more about HCA's customer service options during the pandemic.
Spinal injections were first reviewed by the HTA program in 2011.
- In 2015, the HCA director selected spinal injections for re-review based on newly available published evidence that could change the original determination.
- A re-review of spinal injections was conducted in 2016.
In 2011, HTA conducted an initial evidence review of spinal injections and the Health Technology Clinical Committee (HTCC) determined therapeutic medial branch nerve block injections, intradiscal injections and facet injections are not a covered benefit. Therapeutic lumbar epidural injections, cervical-thoracic epidural injections and sacroiliac joint injections are a covered benefit for the treatment of chronic pain following certain conditions.
In 2015 new literature was identified addressing the use of spinal injections, including new safety concerns voiced by the FDA.
Primary criteria ranking
- Safety = Medium
- Efficacy = High
- Cost = Medium
Documents (2016 assessment)
- Draft key questions: public comment and response
- Final key questions
- Draft report: peer review, public comment and response
- UPDATED Final evidence report
- Final evidence report: appendices
- Final findings and decision
Documents (2011 assessment)
Assessment timeline (2015)
- Draft key questions published: September 1, 2015
- Public comment period: September 1 to 15, 2015
- Final key questions published: October 13, 2015
- Draft report published: December 16, 2015
- Public comment period: December 16 to January 14, 2016
- Final report published: February 12, 2016
- HTCC public meeting: March 18, 2016
Back and neck pain are common conditions, with 60 to 80% percent of U.S. adults afflicted at some time during their life. Back pain, and then neck pain, are the most common causes of disability and loss of productivity. Approximately 90% of low back pain is of the nonspecific type, and a similar majority of neck pain is non-specific. Most patients’ symptoms resolve satisfactorily within a relatively short time span (six weeks). In 5 to 10% of patients, pain does not satisfactorily resolve. The symptoms can be disabling and the social and economic impact of chronic pain is enormous. Discovering the cause for nonspecific low back and neck pain symptoms remains challenging. Some psychosocial risk factors for the progression to chronicity have been identified, but the origin and neurophysiologic pain sensations are poorly understood.
Chronic pain treatment may include pharmacological treatment, physical therapy, psychological care and coping skills, exercise, education, antidepressants, cognitive behavioral therapy and supported self-management, spinal manipulations, electrical stimulation, injections, implanted devices, and other surgical treatment. Treatment strategies generally begin with the least invasive and low risk interventions and progress if the treatments are not effective. Treatment often involves a combination of interventions.
Spinal injections are not usually performed until non-surgical treatments have been given a fair trial and have not provided adequate relief. Intraspinal injections are intended to provide relief by injection of an anti-inflammatory agent (e.g. steroid); and/or anesthetic into the spine or space around the spinal nerves and joints. Intraspinal injections include epidural steroid injections, facet joint injections, medial branch block, sacroiliac joint injections and intradiscal steroid injections.